The Effectiveness of the Palivizumab Programme in Reducing the Risk of Paediatric Asthma: A Population‐Based Study in Ontario, Canada

Asthma incidence declined over this 20-year study; however, smaller declines were observed among children clearly eligible for palivizumab relative to ineligible children. However, exploratory evidence was suggestive of reduced social inequities in asthma post-palivizumab, particularly among possibly eligible children. Larger reductions in asthma might be realized with the introduction of population-based RSV immunization programmes through broader programme eligibility and reductions in severe RSV disease.